Overview

The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2022-01-05

Target enrollment:

Participant gender:

Summary

This study will investigate changes in insulin resistance, lipid metabolism and endocrine profile in HIV-negative subjects exposed to dolutegravir (an antiretroviral drug used in HIV treatment) in order to investigate the role all these different factors may potentially have in weight gain recently reported in clinical cohorts.

Phase:

Phase 1

Details

Lead Sponsor:

Chelsea and Westminster NHS Foundation Trust

Treatments:

Dolutegravir